Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Oral Nirmatrelvir and Ritonavir in Nonhospitalized Vaccinated Patients With Coronavirus Disease 2019
Sarju Ganatra, Sourbha S. Dani, Javaria Ahmad, et al.
Clinical Infectious Diseases (2022) Vol. 76, Iss. 4, pp. 563-572
Open Access | Times Cited: 130

Showing 26-50 of 130 citing articles:

Effectiveness of Nirmatrelvir-Ritonavir for the Prevention of COVID-19–Related Hospitalization and Mortality: A Systematic Literature Review
A. Cha-Silva, M. Gavaghan, Tobias Bergroth, et al.
American Journal of Therapeutics (2024) Vol. 31, Iss. 3, pp. e246-e257
Open Access | Times Cited: 5
Risk of SARS-CoV-2 infection and adverse outcomes among vaccinated patients with tuberculosis
Renin Chang, Sheng-Yin Chen, Tina Yi Jin Hsieh, et al.
Public Health (2025) Vol. 239, pp. 80-86
Closed Access
Real‐world effectiveness and safety of oral azvudine versus nirmatrelvir‒ritonavir (Paxlovid) in hospitalized patients with COVID-19: a multicenter, retrospective, cohort study
Haiyu Wang, Guangying Cui, Ming Cheng, et al.
Signal Transduction and Targeted Therapy (2025) Vol. 10, Iss. 1
Open Access
Cost-effectiveness of nirmatrelvir/ritonavir in COVID-19 patient groups at high risk for progression to severe COVID-19 in the Netherlands
Carlos Duarte, Michel L. Peters, Michelle H. M. de Goeij, et al.
Cost Effectiveness and Resource Allocation (2025) Vol. 23, Iss. 1
Open Access
Efectividad y seguridad de nirmatrelvir + ritonavir en la Covid-19. Estudio NiRCoV
V M González-Rodríguez, M J Hernández-Arroyo, C Rodríguez-Barrueco, et al.
Medicina de Familia SEMERGEN (2025) Vol. 51, Iss. 6, pp. 102462-102462
Open Access
Drugs for COVID-19: An Update
Jessica Ceramella, Domenico Iacopetta, Maria Stefania Sinicropi, et al.
Molecules (2022) Vol. 27, Iss. 23, pp. 8562-8562
Open Access | Times Cited: 23
Characteristics and outcomes of US Veterans at least 65 years of age at high risk of severe SARS-CoV-2 infection with or without receipt of oral antiviral agents
Chris A. Gentry, Phoi N Nguyen, Sharanjeet K. Thind, et al.
Journal of Infection (2023) Vol. 86, Iss. 3, pp. 248-255
Open Access | Times Cited: 15
The Antiviral Effect of Nirmatrelvir/Ritonavir during COVID-19 Pandemic Real-World Data
Vasileios Petrakis, Petros I. Rafailidis, Grigorios Trypsianis, et al.
Viruses (2023) Vol. 15, Iss. 4, pp. 976-976
Open Access | Times Cited: 14
Safety and Efficacy of Outpatient Treatments for COVID-19: Real-Life Data from a Regionwide Cohort of High-Risk Patients in Tuscany, Italy (the FEDERATE Cohort)
Tommaso Manciulli, Michele Spinicci, Barbara Rossetti, et al.
Viruses (2023) Vol. 15, Iss. 2, pp. 438-438
Open Access | Times Cited: 13
Effectiveness of nirmatrelvir-ritonavir for the treatment of patients with mild to moderate COVID-19 and at high risk of hospitalization: Systematic review and meta-analyses of observational studies
Kathiaja Miranda Souza, G. Carrasco, Robin Rojas-Cortés, et al.
PLoS ONE (2023) Vol. 18, Iss. 10, pp. e0284006-e0284006
Open Access | Times Cited: 12
Effectiveness of nirmatrelvir/ritonavir and molnupiravir in non-hospitalized adults with COVID-19: systematic review and meta-analysis of observational studies
Yonatan Moges Mesfin, Joseph E. Blais, Kelemu Tilahun Kibret, et al.
Journal of Antimicrobial Chemotherapy (2024) Vol. 79, Iss. 9, pp. 2119-2131
Open Access | Times Cited: 4
The Impact of Nirmatrelvir-Ritonavir in Reducing Hospitalizations Among High-Risk Patients With SARS-CoV-2 During the Omicron Predominant Era
Mohanad Al‐Obaidi, Ahmet B. Gungor, Sangeetha Murugapandian, et al.
The American Journal of Medicine (2023) Vol. 136, Iss. 6, pp. 577-584
Open Access | Times Cited: 11
Clinical effectiveness of nirmatrelvir plus ritonavir in patients with COVID‐19 and substance use disorders based on real‐world data
Tinghui Liu, Po‐Yu Huang, Jheng‐Yan Wu, et al.
Journal of Medical Virology (2023) Vol. 95, Iss. 5
Closed Access | Times Cited: 11
Expert Consensus: Main Risk Factors for Poor Prognosis in COVID-19 and the Implications for Targeted Measures against SARS-CoV-2
Francisco Javier Candel, Pablo Barreiro, Miguel Salavert, et al.
Viruses (2023) Vol. 15, Iss. 7, pp. 1449-1449
Open Access | Times Cited: 11
Effectiveness of oral antiviral agents on long‐term cardiovascular risk in nonhospitalized patients with COVID‐19: A multicenter matched cohort study
Tinghui Liu, Min‐Hsiang Chuang, Jheng‐Yan Wu, et al.
Journal of Medical Virology (2023) Vol. 95, Iss. 8
Closed Access | Times Cited: 11
Association between nirmatrelvir plus ritonavir and the outcomes of non-hospitalized obese patients with COVID-19
Jheng‐Yan Wu, Mei‐Yuan Liu, Ting-Hui Liu, et al.
International Journal of Antimicrobial Agents (2023) Vol. 62, Iss. 6, pp. 106984-106984
Closed Access | Times Cited: 11
Efficacy and safety of antiviral treatments for symptomatic COVID-19 outpatients: Systematic review and network meta-analysis
Meital Zur, Thalia Peselev, Stav Yanko, et al.
Antiviral Research (2023) Vol. 221, pp. 105768-105768
Closed Access | Times Cited: 11
Cost-Effectiveness of Oral Nirmatrelvir/Ritonavir in Patients at High Risk for Progression to Severe COVID-19 in the United States
Josh J. Carlson, V. Foos, Adam Kasle, et al.
Value in Health (2023) Vol. 27, Iss. 2, pp. 164-172
Open Access | Times Cited: 10
Predictors of nirmatrelvir–ritonavir receipt among COVID-19 patients in a large US health system
Deborah E. Malden, John M. McLaughlin, Vennis Hong, et al.
Scientific Reports (2024) Vol. 14, Iss. 1
Open Access | Times Cited: 3
Nirmatrelvir/Ritonavir Regimen for Mild/Moderately Severe COVID-19: A Rapid Review With Meta-Analysis and Trial Sequential Analysis
George N. Okoli, Nicole Askin, Rasheda Rabbani
The Annals of Family Medicine (2024) Vol. 22, Iss. 4, pp. 336-346
Open Access | Times Cited: 3
Nirmatrelvir plus ritonavir remains effective in vaccinated patients at risk of progression with COVID-19: A systematic review and meta-analysis
Huamin Li, Huai‐rong Xiang, Bei He, et al.
Journal of Global Health (2023) Vol. 13
Open Access | Times Cited: 9
Oral Bemnifosbuvir (AT-527) Vs Placebo in Patients With mild-to-moderate COVID-19 in an Outpatient Setting (MORNINGSKY)
Arantxa Horga, Rebecca Saenz, Gürdal Yılmaz, et al.
Future Virology (2023) Vol. 18, Iss. 13, pp. 839-853
Open Access | Times Cited: 9
Coronavirus disease 2019 rebounds following nirmatrelvir/ritonavir treatment
Chih‐Cheng Lai, Po‐Ren Hsueh
Journal of Medical Virology (2022) Vol. 95, Iss. 2
Open Access | Times Cited: 14
Effectiveness and Adverse Events of Nirmatrelvir/Ritonavir Versus Molnupiravir for COVID-19 in Outpatient Setting: Multicenter Prospective Observational Study
Jin Ju Park, Hyunji Kim, Yong Kyun Kim, et al.
Journal of Korean Medical Science (2023) Vol. 38, Iss. 42
Open Access | Times Cited: 8
Clinical Effectiveness of Ritonavir-Boosted Nirmatrelvir—A Literature Review
Sydney Paltra, Tim Conrad
Advances in respiratory medicine (2024) Vol. 92, Iss. 1, pp. 66-76
Open Access | Times Cited: 2

Scroll to top